新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » PLoS ONE:注射特异染料就可以治疗黑色素瘤

PLoS ONE:注射特异染料就可以治疗黑色素瘤

来源:生物谷 2013-08-24 20:35

2013年8月24日讯 /生物谷BIOON/--美国佛罗里达Moffitt癌症研究中心的一项研究为黑色素瘤病人带来了希望。科学家研究了注射用PV-10是否能够影响黑色素瘤。PV-10是一种由玫瑰红演变而来的一种可溶性染料,常用于对眼睛中受损细胞着色。之前研究表明PV-10能够激起对黑色素瘤细胞的强烈免疫反应。

Moffitt癌症研究中心Shari Pilon-Thomas教授称,采用注射疗法治疗黑色素瘤已经有四十多年的历史了,但是都没有像我们注射PV-10这样的治疗效果。

科学家对黑色素瘤小鼠注射单一剂量的PV-10。结果发现皮肤癌损伤明显变小,而且扩散到肺部的黑色素瘤也显著性的减少。科学家称该染料似乎能够产生强烈的抗癌细胞免疫反应,或许比现有的免疫制剂都安全。

Amod A. Sarnaik医生称,我们已经开始在晚期黑色素瘤病人中进行首次临床PV-10实验了。注射PV-10之后,我们也在病人体内发现强烈的抗癌细胞反应,并监测到了黑色素瘤也发生变化。(生物谷Bioon.com)

Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer.

Toomey P, Kodumudi K, Weber A, Kuhn L, Moore E, Sarnaik AA, Pilon-Thomas S.

Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine an underlying immune mechanism, the murine B16 melanoma model and the MT-901 breast cancer model were utilized. In BALB/c mice bearing MT-901 breast cancer, injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions. In a murine model of melanoma, B16 cells were injected into C57BL/6 mice to establish one subcutaneous tumor and multiple lung lesions. Treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases. Anti-tumor immune responses were measured in splenocytes collected from mice treated with IL PBS or PV-10. Splenocytes isolated from tumor bearing mice treated with IL PV-10 demonstrated enhanced tumor-specific IFN-gamma production compared to splenocytes from PBS-treated mice in both models. In addition, a significant increase in lysis of B16 cells by T cells isolated after PV-10 treatment was observed. Transfer of T cells isolated from tumor-bearing mice treated with IL PV-10 led to tumor regression in mice bearing B16 melanoma. These studies establish that IL PV-10 therapy induces tumor-specific T cell-mediated immunity in multiple histologic subtypes and support the concept of combining IL PV10 with immunotherapy for advanced malignancies.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库